Back to Natixis Natixis

TXG

12 quarters

Position history for NatixisNatixis's holdings in 10x Genomics, Inc.

No. Natixis exited its TXG (10x Genomics) position in Q3 2025. Its Q2 2025 13F listed 300 shares worth $3,474. Natixis first reported TXG in Q4 2020 and held it in 8 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$17.1M

Total Shares Change

-121,006

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q3
Latest
Exited
0
-100.0%
$00.0%$11.34
0
2025-Q2
New
300
-
$3,4740.0%$11.73
21
2023-Q2
Exited
0
-100.0%
$00.0%$56.70
0
2023-Q1
Decreased
1,915
-5.9%
$106,8380.0%$52.05
0
2022-Q4
New
2,035
-
$74,1550.0%$36.44
29
2022-Q2
Exited
0
-100.0%
$00.0%$46.20
0
2022-Q1
Decreased
26,537
-49.5%
$2M0.0%$74.74
0
2021-Q4
Increased
52,550
+27.0%
$7.8M0.0%$150.88
34
2021-Q3
New
41,392
-
$6M0.0%$145.94
38
2021-Q2
Exited
0
-100.0%
$00.0%$201.33
0
2021-Q1
Decreased
46,152
-61.9%
$8.4M0.0%$168.22
0
2020-Q4
New
121,006
-
$17.1M0.1%$142.61
39

Other major holders of TXG: FMR LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used